EBV Infection. > Cellular Immune Response Profiling. > Humoral Immune Response Profiling EBV. ImmunoTools

Transcription

1 EBV ImmunoTools Peptide Tools to Study EBV EBV Infection > Cellular Immune Response Profiling Antigen spanning EBV PepMix Peptide Pools PepMix Collection EBV > Humoral Immune Response Profiling EBV RepliTope Microarrays for Marker Discovery RepliTope Antigen Collection EBV Innovative Peptide Solutions

2 About Epstein-Barr Virus Epstein-Barr virus (EBV or HHV-4) belongs to the family of Herpesviridae and is known as the cause of infectious mononucleosis. Being able to establish a long-term, latent infection in human B cells, it is prevalent in the adult population (worldwide 90%). The virus is associated with a range of human diseases and cancers, particularly Hodgkin s and Burkitt s lymphoma and nasopharyngal carcinoma. Furthermore, EBV has been described to be the main cause of post-transplant lymphoproliferative disease (PTLD) in immune suppressed transplant patients. Finally, EBV increases the risk of certain autoimmune diseases, especially lupus erythematosus, rheumatoid arthritis and multiple sclerosis. The latent EBV Antigens During latent infection EBV expresses a small number of genes (e.g. EBNA1-3 and LMP1-2). Three major types of latency can be differentiated by their distinct expression patterns and are associated with the various types of diseases and cancer. Both, humoral and cellular (mainly CTL) immune responses play a role in controlling the primary and the latent phases of EBV infection. About JPT Peptide Technologies JPT Peptide Technologies is a DIN ISO 9001:2008 certified and GCLP compliant integrated company providing innovative peptide based products focusing on: Immune monitoring and diagnostics Seromarker discovery & validation Vaccine target discovery Peptide lead identification & optimization Biomarker quantification by targeted proteomics Enzyme substrate identification & sensitivity profiling

3 Tools to Study Cellular Immune Responses PepMix Peptide Pools for antigen specific stimulation of CD4 + and CD8 + T-cells in Immune monitoring of transplant patients Disease progression monitoring Immune monitoring during treatment Epitope mapping Benefits of PepMix More reliable than whole protein antigens Simultaneous detection of CD4 and CD8 responses High batch-to-batch reproducibility EBV PepMixes Individual peptide pools comprise overlapping peptide scans through single immunodominant antigens: BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, GP340/GP350, LMP1 and LMP2. PepMix Collection EBV The PepMix Collection provides peptide pools (2 aliquots each) of 13 different antigens in one plate for fast and economic immune response profiling. Includes the following PepMix peptide pools: BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, GP340/GP350, LMP1 and LMP2. Contact us for customized PepMix peptide pools or indivdual peptides: peptides@jpt.com Select specific antigens for immune monitoring.

4 Tools to Study Humoral Immune Responses Peptide Microarrays for humoral response profiling in Seromarker discovery Antibody epitope mapping & discovery Immune monitoring Benefits of RepliTope Hundreds of identical microarray copies Peptides free of truncated sequences Only small sample amounts needed Applicable to many biological samples (e.g. serum, plasma, antibody) Low background on glass surface EBV RepliTopes Peptide microarrays display overlapping peptides through single immunodominant antigens: BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, GP340/GP350, LMP1 and LMP2. RepliTope Antigen Collection EBV Overlapping peptides through 13 immunodominant proteins combined on one microarray for maximum efficacy in a single experiment. Featured antigens: BMLF1, BMRF1, BRLF1, BZLF1, EBNA-LP, EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, GP350/ GP340, LMP1 and LMP2. Contact us for tailored PepStar peptide microarrays or ELISA and full assay service: peptides@jpt.com JPT s peptide microarrays are produced to meet highest quality standards in an ISO 9001:2008 regulated clean room environment.

5 References A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses Pawlowski et al., Application Note (2013) PepMix Peptide Pools for Clinical Applications: T Cell Therapy for Viral Infections After Hematopoietic Stem Cell Transplant Leen et al., Application Note (2012) Peptide-Microarray Analysis of In-Silico Predicted Epitopes for the Serological Diagnosis of Toxoplasma Gondii in Infected Humans Maksimov et al., Clin. Vaccine Immunol. (2012) T-cell Therapy for EBV-Associated Nasopharyngeal Carcinoma: Preparative Lymphodepleting Chemotherapy Does Not Improve Clinical Results Secondino et al., Ann. Onc. (2011) Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals Tomaras et al., Journal of Virology (2011) Effective and Long-term Control of EBV PTLD After Transfer of Peptide-Selected T Cells Moosmann et al., Blood (2010) Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma Louis et al., J. Immunotherapy (2010) Testimonials The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving its peptide based services. Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany

6 Please visit JPT at for Catalog Products such as EBV related PepMixes and RepliTopes for Custom Products & Services for Peptide Related Collaborations Not found what you are looking for? Contact our customer support at to get a quote for your customized peptide pool or peptide microarray! Graphical material title: Human Sebastian Kaulitzki - Fotolia.com / Virus Marko Reschke Innovative Peptide Solutions Subject to changes. 08/2013 JPT Peptide Technologies peptide@jpt.com European Head Office T F USA/Canada T F